Is cisplatin-induced cell death always produced by apoptosis?

Molecular Pharmacology

Volumn 59, Issue 4, 2001, Pages 657-663

  Gonzalez, Victor M ^a   Fuertes, Miguel A ^b   Alonso, Carlos ^b   Perez, Jose M ^b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MITOCHONDRIAL DNA; PHOSPHOLIPID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER TUMOR; CANCER THERAPY; CELL DEATH; CROSS LINKING; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DNA PROTEIN COMPLEX; HEAD AND NECK TUMOR; LUNG NON SMALL CELL CANCER; MEMBRANE CHANNEL; MICROFILAMENT; OVARY TUMOR; PRIORITY JOURNAL; SHORT SURVEY; TESTIS TUMOR; UTERINE CERVIX CANCER;

EID: 0035060354     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.59.4.657     Document Type: Short Survey

References (55)

1. Mammalian cell death proteases: A family of highly conserved aspartate specific cysteine proteases
2. Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance
3. Bcl-2 family protein expression and platinum drug resistance in ovarian carcinoma
4. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin
5. Basic fibroblast growth factor sensitizes NIH 3T3 cells to apoptosis induced by cisplatin
6. Apoptosis and cancer chemotherapy
7. The mechanism of action of cisplatin: From adducts to apoptosis
8. Intracellular ATP levels determine cell death fate by apoptosis or necrosis
9. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2
10. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis
11. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocites is dependent of the levels of drug accumulation and DNA adduct formation
12. Apoptosis in cancer therapy: Crossing the threshold
13. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system
14. Cellular accumulation of the anticancer agent cisplatin: A review
15. Cell death mechanisms and the immune system
16. 2]
17. Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines
18. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines
19. Apoptosis induced by anticancer agents
20. The CARD domain: A new apoptotic signalling motif
21. Ras mutation and platinum resistance in human ovarian carcinomas in vitro
22. Purification of nuclear proteins that bind to cisplatin-damage DNA: Identity with high mobility group proteins 1 and 2
23. Structure, recognition and processing of cisplatin-DNA adducts
24. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak up-regulation and the functional status of p53
25. HTLV-1 Tax protein sensitizes cells to apoptotic cell death induced by DNA damaging agents
26. New platinum antitumor complexes
27. Abrogation of mitochondrial cytochrome C release and caspase-3 activation in acquired multidrug resistance
28. Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis
29. Cytochrome C and dATP-dependent formation of Apaf-1/caspase 9 complex initiates an apoptotic protease cascade
30. The 40-kDA subunit of DNA fragmentation and chromatin condensation during apoptosis
31. Reaction mechanism of human DNA repair excision nuclease
32. An induced proximity model for caspase-8 activation
33. Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis
34. Current status of the development of trans-platinum antitumor drugs
35. 2(isopropylamine)(amine')] complexes
36. Cellular and molecular determinants of cisplatin resistance
37. Effects of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line
38. Cisplatin
39. Bcl-2 family proteins: Role in dysregulation of apoptosis and chemoresistance in cancer
40. Intracellular calcium stores are not required for Bcl-2 mediated protection to apoptosis
41. Platinum complexes for the treatment of cancer: Why the search goes on
42. A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents
43. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process
44. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma
45. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc
46. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient chinese hamster ovary cells
47. Autoactivation of precaspase-9 by Apaf-1 mediated oligomerization
48. Human KU autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase
49. Current status of platinum-based antitumor drugs
50. 2+-dependent endonuclease in apoptosis and its inhibition by poly(ADP-ribose) polymerase
51. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins
52. The response of cellular proteins to cisplatin-damage DNA
53. p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells
54. A role for c-myc in chemically induced renal-cell death
55. The roles of caspase-3 and bcl-2 chemically induced apoptosis but not necrosis of renal epithelial cells